Prohost Biotech
HomeArticlesImpacting NewsCorcept Therapeutics: Overall Survival Primary Endpoint Met In Pivotal Phase 3 Rosella Trial OF Relacorilant in Patients With Platinum-Resistant Ovarian Cancer
Impacting News
Premium

Corcept Therapeutics: Overall Survival Primary Endpoint Met In Pivotal Phase 3 Rosella Trial OF Relacorilant in Patients With Platinum-Resistant Ovarian Cancer

Corcept Therapeutics Yesterday, January 22, 2026,  Corcept Therapeutics ( CORT ) - a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, on...
P

Prohost Biotech

1 min read
47
0

Unlock Premium Content

This article contains exclusive content for our premium subscribers. Join our community to access in-depth research, expert insights, and comprehensive analysis.

Unlimited articles
Expert analysis
Research reports

Tags

Corcept Therapeutics (CORT)

Comments (0)

Please sign in to join the discussion

Related Articles

Impacting News
Premium

Axsome Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Total 1Q 2026 net product revenue of   $191.2 million, representing 57% year-over-year growth   AUVELITY ®   1Q 2026 net product sales of   $153.2 million, representing 59% year-over-year growth   SUN...
P

Prohost Biotech

May 6, 2026

1m
254
Impacting News
Premium

Neurocrine Biosciences Acquires Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio

Neurocrine ...
P

Prohost Biotech

Apr 8, 2026

1m
196
Impacting News
Premium

FDA Approved Lilly's Foundayo™ (orforglipron), the Only GLP-1 Pill for Weight Loss That Can Be Taken Any Time of Day Without Food or Water Restrictions

Eli Lilly in the NEWS INDIANAPOLIS, April 1, 2026 /PRNewswire/, Eli Lilly and Company ( LLY ) , announced the U.S. FDA approved Foundayo™ (orforglipron) for adults with obesity, or overweight with wei...
P

Prohost Biotech

Apr 2, 2026

1m
232